Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
4.9.2018

FDA Orders “Unique” Restriction on Essure

By Brian Lynch
In The News, You Should Know, For Consumers

The FDA has announced a unique restriction on Essure

Essure, the permanent birth control device made by Bayer, has come under serious scrutiny in recent years. Concerns over safety and numerous reported complications have contributed to the device being pulled from sale in most global markets, save for the United States. Now, following renewed criticisms from patients and attorneys, the Food and Drug Administration has issued what it calls a “unique type” of restriction on Essure.

The change will restrict Essure sales to doctors and healthcare facilities that provide patients with a specific brochure detailing the risks of the device, specifically referencing possible perforation of the uterus and fallopian tubes, device migration, and allergic reactions to nickel. The FDA added that only patients who read and sign the brochure will be able to have the device implanted.

“Despite previous efforts to alert women to the potential complications of Essure, we know that some patients still aren’t receiving this important information,” FDA Commissioner Scott Gottlieb said in a statement Monday. “This is simply unacceptable.”

This change in policy is likely a result of the FDA’s recent statement about the device, which was delivered following a meeting with concerned patients who were affected by Essure. In the official statement, the FDA revealed that they had received nearly 12,000 reports of complications in 2017. The bulk of these complaints were received in the last quarter of the year, through cases made available by plaintiff attorneys overseeing the litigation.

While this isn’t the outright ban that most advocates and injured parties have been pleading for, it’s further evidence to support the significant risks posed by the device.

Share

No Comments

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Media Appearances
  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
    • Ed Wallace
  • Practice Areas
    • Consumer Protection
    • Mass Tort Litigation
    • Business & Commercial Litigation
    • Healthcare Litigation
    • Employment Litigation
  • Cases
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • Featured Investigations
  • The Firm
    • News releases
    • Around The World
    • Our Professionals
    • Chicago
  • You Should Know
    • For Investors
    • For Businesses
    • For Consumers
  • Featured Cases
  • awards
  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP